Table 2 Number (%) of patients with adverse events during the double-blind period (2% in any group, safety population)

From: Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension

Preferred term n (%)

Aliskiren 300 mg (N=331)

Aliskiren 150 mg (N=323)

Aliskiren 75 mg (N=332)

Ramipril 5 mg (N=329)

Any AEs

52 (15.7)

60 (18.6)

57 (17.2)

68 (20.7)

AE >2% in any group

 Dizziness

10 (3.0)

15 (4.6)

15 (4.5)

13 (4.0)

 Headache

6 (1.8)

13 (4.0)

6 (1.8)

12 (3.6)

 Cough

4 (1.2)

3 (0.9)

2 (0.6)

17 (5.2)

Discontinuation because of AEs

9 (2.7)

16 (5.0)

14 (4.2)

8 (2.4)

Any SAE

1 (0.3)

2 (0.6)

3 (0.9)

1 (0.3)

  1. Abbreviations: AE, adverse event; SAE, serious adverse event.
Back to article page